帕金森病丘脑底核脑深部电刺激五年结局
INTREPID试验是一项随机双盲假对照研究,评估双侧丘脑底核脑深部电刺激治疗帕金森病的五年长期结局与安全性。313例入组,191例接受DBS,137例完成研究;5年时UPDRS-III运动评分较基线改善36%,日常生活能力改善22%,异动症减少70%,左旋多巴等效剂量降低28%且保持稳定。
要点
- 5年时UPDRS-III运动评分改善36%,日常生活能力改善22%。
- 异动症评分5年减少70%,左旋多巴等效剂量降低28%且稳定。
- 最常见严重不良事件为感染(9例),10例死亡与研究无关。
核心结论
- 尽管STN-DBS疗效略有下降,可能因疾病进展,帕金森病患者在5年随访中运动与日常生活评分持续显著改善,抗帕金森病药物稳定减少。
研究设计与样本
- 前瞻性随机(3:1)12周双盲假对照研究,美国23个运动障碍中心,开放标签5年随访。
- 2013年5月至2022年12月植入并随访Vercise DBS系统,共入组313例,191例接受DBS系统,137例(72%)完成研究。
- 入组要求:双侧特发性帕金森病、运动症状超过5年、每日运动功能差超过6小时、改良Hoehn和Yahr量表评分高于2、关期UPDRS-III评分30或以上、开期UPDRS-III改善33%或以上。
主要发现
- 关期UPDRS-III从基线均值42.8改善至第1年21.1(51%;95%CI 49%-53%;P<.001)和第5年27.6(36%;95%CI 33%-38%;P<.001)。
- 关期UPDRS-II从基线20.6改善至第1年12.4(41%;95%CI 38%-42%;P<.001)和第5年16.4(22%;95%CI 18%-23%;P<.001)。
- 异动症评分从基线4.0降至第1年1.0(75%;95%CI 73%-75%;P<.001)和第5年1.2(70%;95%CI 63%-75%;P<.001)。
- 左旋多巴等效剂量第1年降低28%,第5年保持稳定(28%;95%CI 26%-31%;P<.001)。
- 最常见严重不良事件为感染(9例参与者),报告10例死亡,均与研究无关。
关键数值与推荐
- 关期UPDRS-III 5年改善36%(95%CI 33%-38%;P<.001)。
- 关期UPDRS-II 5年改善22%(95%CI 18%-23%;P<.001)。
- 异动症评分5年减少70%(95%CI 63%-75%;P<.001)。
- 左旋多巴等效剂量5年降低28%(95%CI 26%-31%;P<.001)。
临床怎么用
- 对于中度至晚期帕金森病患者,双侧STN-DBS可在5年内持续改善运动功能、日常生活能力和异动症。
- STN-DBS可稳定减少抗帕金森病药物剂量,左旋多巴等效剂量5年降低28%。
- 需关注感染等严重不良事件,本研究中感染为最常见严重不良事件(9例)。
局限性
- 开放标签随访部分可能存在偏倚。
- 疗效略有下降可能与疾病进展有关,但研究未设对照组验证。
- 72%参与者完成5年研究,存在失访偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The Implantable Neurostimulator for the Treatment of Parkinson's Disease (INTREPID) trial was a randomized, double-blind, sham-controlled study of subthalamic nucleus (STN) deep brain stimulation (DBS) for the treatment of Parkinson disease (PD). OBJECTIVE: To evaluate the long-term (5-year) outcomes and safety of STN-DBS for PD. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective, randomized (3:1), 12-week double-blind sham-controlled study at 23 movement disorder centers across the US with an open-label 5-year follow-up. Patients were implanted and followed up with the Vercise DBS system from May 2013 to December 2022. Eligibility required diagnosis of bilateral idiopathic PD with more than 5 years of motor symptoms, more than 6 hours per day of poor motor function, modified Hoehn and Yahr Scale scores higher than 2, Unified Parkinson's Disease Rating Scale (UPDRS-III) score of 30 or higher (medication-off state), and 33% or higher improvement in UPDRS-III medication-on score. INTERVENTION: Bilateral STN-DBS for moderate to advanced PD. MAIN OUTCOMES AND MEASURES: Primary outcomes included changes in UPDRS and dyskinesia scores, quality-of-life measures, and safety assessments. Exploratory analyses included medication reduction and DBS association with motor signs. RESULTS: A total of 313 patients were enrolled with 191 receiving the DBS system, and 137 participants (72%) completed the study. The study population had a mean (SD) age of 60 (7.9) years, with 139 (73%) male participants. Motor function without medication as measured by UPDRS-III improved from a mean (SD) of 42.8 (9.4) to 21.1 (10.6) at year 1 (51%; 95% CI, 49%-53%; P < .001) and 27.6 (11.6) at year 5 (36%; 95% CI, 33%-38%; P < .001). Activities of daily living without medication as measured by UPDRS-II improved from a mean (SD) of 20.6 (6.0) to 12.4 (6.1) at year 1 (41%; 95% CI, 38%-42%; P < .001) and 16.4 (6.5) at year 5 (22%; 95% CI, 18%-23%; P < .001). Dyskinesia scores decreased from 4.0 (5.1) to 1.0 (2.1) at year 1 (75%; 95% CI, 73%-75%; P < .001) and to 1.2 (2.1) at year 5 (70%; 95% CI, 63%-75%; P < .001). The levodopa equivalent dose was reduced by 28% at year 1, remaining stable at year 5 (28%; 95% CI, 26%-31%; P < .001). The most common serious adverse event was infection (9 participants). Ten deaths were reported, none related to the study. CONCLUSIONS AND RELEVANCE: Although STN-DBS outcomes declined slightly, possibly due to the progressive nature of the disease, patients with PD sustained significant improvement in motor and activities of daily living scores, along with a stable reduction in anti-parkinsonian medication over the 5-year follow-up period.
引用
- Starr PA, Shivacharan RS, Goldberg E, et al. Five-Year Outcomes from Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson Disease. JAMA Neurol. 2025. PMID: 40952750. doi:10.1001/jamaneurol.2025.3373
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。